Please login to the form below

Not currently logged in

BMS exits hep C, diabetes and neuroscience drug discovery

Will discontinue 'broad-based discovery work' in the therapy areas

Bristol-Myers Squibb (BMS)Bristol-Myers Squibb (BMS) has called time on R&D in several therapy areas to focus more on priority fields, such as immuno-oncology, and bringing its late-stage pipeline to fruition.

The company will discontinue 'broad-based discovery work' in neuroscience, which has been a particularly difficult area for pharma of late, with a number of late-stage pipeline failures.

BMS will also halt such discovery work in hepatitis C and diabetes, but will keep supporting existing or late-stage candidates in two therapy areas.

Meanwhile, the plans will see BMS “executing development, regulatory and commercial plans” in diabetes and hepatitis C, while it focuses more wholeheartedly on HIV, hepatitis B, heart failure, oncology, immunoscience and fibrotic disease research.

Francis Cuss, BMS' chief scientific officer, said: “We have decided to shift R&D toward a more speciality biopharma model that focuses on the areas of significant unmet medical need, driving near-term growth through our current late-stage portfolio and on ensuring the long-term growth of the company by evolving the disease areas and drug platforms on which we concentrate our research efforts.”

Part of these plans will see BMS “evolve the disease areas and drug platforms on which we concentrate our research efforts to drive growth for the company in 2020 and beyond”, the company said.

But it pledged to continue to advance its oral anticoagulant Eliquis (apixaban); cancer drugs Sprycel (dasatinib) and Erbitux (cetuximab); Orencia (abatacept) for arthritis; hepatitis B treatment Baraclude (entecavir); and HIV drugs Reyataz (atazanavir sulfate)/Sustiva (efavirenz).

BMS also said it would increase investment in immuno-oncology, an area in which it see “significant opportunity” and which has already yielded its antibody treatments Erbitux, Yervoy (ipilimumab) and its anti-PD1 candidate nivolumab.

Meanwhile, BMS last year signed an academic immune-oncology research alliance and in 2009 paid $2.4bn for US biotech firm Medarex, which specialises in human antibody-based therapeutics.

Diabetes research at BMS

Despite promising to keep up with its current diabetes franchise, the change in R&D direction throws into question BMS's billion-dollar diabetes alliance with AZ.

This stepped up a gear last year with the $7bn purchase of Amylin, the company behind Byetta and Bydureon, but recently the partners suffered a setback with Onglyza (saxagliptin) and are still waiting for US approval for Forxiga (dapagliflozin).

Analysts are already sizing up the sale prospects for BMS' diabetes franchise, with one predicting the company's interests outside the US could be worth $4bn-6bn.

The company is not alone in making research cuts, with this year seeing much deeper cuts at AstraZeneca, Merck & Co, Novartis and Shire.

But BMS' plans will reportedly hit just a small number of employees, with some 70 to 75 research positions set to be cut by the end of the year, and up to a further 300 facing changes in their roles.

Article by
Dominic Tyer

11th November 2013

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

How Far Do You Want To Go?
Join OPEN Health's virtual careers event on Tuesday 10th November, 15:00–17:00 GMT and discover where a career in medical communications could take you…...
"Fishbowl" Web Meeting for Internal POA Discussions: a Customer Story
Learn how our client successfully carried out a set of three virtual plan of action (POA) discussions, including one internal “Fishbowl” web meeting....
Whats the difference between patient engagement and patient experience?
We all talk a lot about patient engagement and patient experience. And sometimes, these terms are used interchangeably across the industry. But while they’re both important, they’re not the same....